For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new ...

Phase II CONFIDENCE study data reveal that simultaneous initiation of Kerendia and Jardiance significantly improves UACR and ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

She is among many patients now asking why, with no apparent change in their blood test results, chronic kidney disease (CKD) ...

"Omega-3 fatty acids have been known for their cardioprotective effects and they have broad anti-inflammatory properties, ...

Simultaneous treatment start with finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Berlin Saturday, June 7, 2025, 1 ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...